SCHEMBL4240771

SCHEMBL4240771

FC(F)(F)c1ccc([C@H](Oc2ccccc2)C2CCNCC2)cc1

nearest known ligand 0.90

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.77
SLC6A4 P31645 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240773 1.00 SLC6A2 (0.77) SLC6A2SLC6A4
SCHEMBL3891610 0.95 SLC6A2 (0.85) SLC6A2SLC6A4
SCHEMBL3895104 0.85 SLC6A2 (0.67) SLC6A2SLC6A4
SCHEMBL3895066 0.82 SLC6A2 (0.75) SLC6A2SLC6A4
SCHEMBL3901071 0.81 SLC6A2 (0.65) SLC6A2SLC6A4
SCHEMBL3725941 0.80 SLC6A2 (0.86) SLC6A2SLC6A4
SCHEMBL3715944 0.80 SLC6A2 (0.86) SLC6A2SLC6A4
SCHEMBL3719834 0.80 SLC6A2 (0.86) SLC6A2SLC6A4
SCHEMBL13152467 0.80 SLC6A2 (0.86) SLC6A2SLC6A4
SCHEMBL3719829 0.80 SLC6A2 (0.86) SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491735-B2 Chemokine receptor binding compounds GENZYME CORPORATION (US) 2009-02-17 US disclosed
EP-1708703-A4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2008-04-09 EP disclosed
EP-1708703-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-10-11 EP disclosed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 US disclosed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277670-A1 Chemokine receptor binding compounds CCR5, CXCR3, CCL5 SLC6A2 3198/4885SLC6A4 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.